Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Depreciation & Amortization (CF) (2018 - 2025)

Historic Depreciation & Amortization (CF) for Autolus Therapeutics (AUTL) over the last 5 years, with Q3 2025 value amounting to $2.1 million.

  • Autolus Therapeutics' Depreciation & Amortization (CF) rose 727.55% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.1 million, marking a year-over-year increase of 883.46%. This contributed to the annual value of $7.6 million for FY2024, which is 1506.47% up from last year.
  • Autolus Therapeutics' Depreciation & Amortization (CF) amounted to $2.1 million in Q3 2025, which was up 727.55% from $2.1 million recorded in Q2 2025.
  • Autolus Therapeutics' Depreciation & Amortization (CF)'s 5-year high stood at $2.1 million during Q2 2025, with a 5-year trough of $1.4 million in Q3 2023.
  • Moreover, its 4-year median value for Depreciation & Amortization (CF) was $1.9 million (2024), whereas its average is $1.8 million.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first tumbled by 2338.89% in 2023, then skyrocketed by 4053.66% in 2024.
  • Over the past 4 years, Autolus Therapeutics' Depreciation & Amortization (CF) (Quarter) stood at $1.6 million in 2022, then rose by 7.64% to $1.8 million in 2023, then rose by 7.89% to $1.9 million in 2024, then increased by 8.56% to $2.1 million in 2025.
  • Its Depreciation & Amortization (CF) was $2.1 million in Q3 2025, compared to $2.1 million in Q2 2025 and $2.0 million in Q1 2025.